# An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase

> **NCT02368717** · PHASE3 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 281 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Mesalazine Enema
- **DRUG:** Placebo Enema

## Key facts

- **NCT ID:** NCT02368717
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2017-01-05
- **Final completion:** 2017-07-25
- **Target enrollment:** 281 (ACTUAL)
- **Last updated:** 2017-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02368717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02368717, "An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02368717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*